Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

Fig. 2

a Overall survival of patients with cutaneous melanoma (cut-off 16.0 ng/ml). Overall survival of patients with cutaneous melanoma depending on ECP level (n = 45). Patients with an ECP level of 16.0 ng/ml or greater (n = 24) lived shorter (median OS = 12 months) than patients with less than 16.0 ng/ml serum ECP (n = 21; median OS = 28 months; p = 0.0597) at the time of metastatic disease (stage 4). b Overall survival of patients with cutaneous melanoma (cut-off 12.2 ng/ml). Overall survival of patients with an ECP level of 12.2 ng/ml or greater (n = 29; median OS = 12 months) and of patients with less than 12.2 ng/ml serum ECP (n = 16; median OS not reached) at the time of stage 4 diagnosis within patients having cutaneous melanoma (n = 45). The difference is statistically significant at p = 0.0393

Back to article page